LabCorp Acquires Covance Genomics Laboratory
LabCorp acquired Covance Genomics Laboratory (CGL) and its associated genomic analysis business.
We are excited to announce LabCorp's acquisition of the Covance Genomics Laboratory (CGL) and its associated genomic analysis business. This state-of-the-art laboratory located in Seattle provides leading-edge complex genomic analysis, including gene expression array studies and next generation sequencing applications, to support drug development activity for pharmaceutical and biotechnology companies. In addition to offering these services to our existing clients, LabCorp and Covance have entered into a five-year services agreement to collaborate and continue offering specialty genomic services to Covance clients.
The platforms and capabilities available at this laboratory are complementary to and broaden LabCorp's existing global Clinical Trials laboratory network, and we will work to develop and expand these capabilities in the future. Equally impressive are the skills and accomplishments of the more than 50 scientists and staff who are now members of the LabCorp team.
In addition to global safety and specialty testing services, LabCorp can now offer clients a more comprehensive set of genomic services in earlier stages of drug development. The acquisition enhances LabCorp's existing biomarker development and companion diagnostics capabilities and it confirms our commitment to expand and enhance our industry-leading genomic services -- including translational biomarkers, computational biology, and next generation sequencing.
LabCorp Clinical Trials already provides a number of core genomic services -- including mutation analysis, pharmacogenetics, and pharmacogenomics -- from our global locations in North America, Belgium and China to support early- to late-phase clinical trials. This acquisition significantly expands our current offering by allowing LabCorp to provide clients with a more comprehensive set of genomic services from preclinical and early development to late-stage development.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
